Washington, D.C. – September 20, 2004 – Prestwick Pharmaceuticals, Inc., a CNS specialty pharmaceutical company, announced today the acquisition of rights to commercialize tetrabenazine in Canada under the brand name Nitoman from Cambridge Laboratories, UK.

Tetrabenazine is a dopamine depletor approved in Canada for the treatment of a series of hyperkinetic movement disorders. Approximately 50,000 in Canada suffer from these disorders, which are characterized by excessive, involuntary purposeless and repetitive movements which may involve the face, limbs or the entire body.

Tetrabenazine is also approved for use in the UK, and number of European countries, and Australia, and is currently undergoing Phase III pivotal trials in the U.S. Prestwick plans to file an NDA for tetrabenazine in the United States later this year.

“ Acquiring the rights to Nitoman in Canada represents a significant commercial opportunity for Prestwick on a number of fronts,” said David Cory, President and Chief Operating Officer of Prestwick. This move allows us to build infrastructure to support Canadian healthcare practitioners’ and patients’ use of Nitoman and begin to generate revenues for Prestwick as we conduct our Phase III program toward approval of tetrabenazine in the United States.“

“Licensing commercial rights for Nitoman to Prestwick Pharmaceuticals makes good business sense and ensures that Nitoman will be freely available to patients in Canada who suffer from these disorders,” said Mark Evans, CEO of Cambridge Laboratories. “This move allows Cambridge to focus on maximizing the full potential of tetrabenazine on a global basis, while Prestwick Pharmaceuticals manages the development and commercial growth of tetrabenazine in North America”.

About Prestwick Pharmaceuticals
Prestwick Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company that focuses on treatments for CNS disorders. The company has multiple product candidates in clinical development for Huntington’s Chorea, Parkinson’s Disease, and Schizophrenia. Prestwick plans to commercialize its lead product, tetrabenazine, in the U.S. as soon as FDA approval is obtained.

About Cambridge Laboratories
Cambridge Laboratories, based in Newcastle, UK, is a privately owned pharmaceutical company providing specialist products to serve the needs of the secondary healthcare physician. Cambridge’s focus is in the areas of CNS, Oncology, and niche hospital products. In 1997, Cambridge Laboratories acquired worldwide marketing rights for tetrabenazine.